Overview

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Status:
Completed
Trial end date:
2018-04-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Ascletis Pharmaceuticals Co., Ltd.